{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of 95% confidence interval (CI) was not estimable due to the small number of events.","groupId":"OG000","lowerLimit":"6.4","upperLimit":"NA","value":"9.2"},{"comment":"The upper limit of 95% CI was not estimable due to the small number of events.","groupId":"OG001","lowerLimit":"6.1","upperLimit":"NA","value":"8.5"},{"comment":"The upper limit of 95% CI was not estimable due to the small number of events.","groupId":"OG002","lowerLimit":"5.5","upperLimit":"NA","value":"13.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"description":"DR is defined, for participants with an OR per RECIST version 1.1, as the time from the first documentation of objective tumor response (CR \\[disappearance of all target lesions\\] or PR \\[\\>=30% decrease under the baseline of the sum of diameters of all target measurable lesions\\]) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Avelumab 10 milligram (mg)/kilogram (kg) given as a 1-hour intravenous (IV) infusion every 2 weeks (Q2W) in 4-week cycles.","id":"OG000","title":"Avelumab"},{"description":"Avelumab 10 mg/kg given as a 1-hour IV Q2W in 4-week cycles + pegylated liposomal doxorubicin (PLD) 40 mg/square meter given as a 1-hour IV infusion every 4 weeks (Q4W) in 4-week cycles.","id":"OG001","title":"Avelumab + PLD"},{"description":"PLD 40 mg/square meter given as a 1-hour IV infusion Q4W in 4-week cycles.","id":"OG002","title":"Pegylated Liposomal Doxorubicin (PLD)"}],"paramType":"MEDIAN","populationDescription":"The secondary efficacy endpoint was analyzed in FAS. The FAS included all participants who were randomized. Number analyzed are participants with confirmed CR or PR in the FAS within each treatment group.","reportingStatus":"POSTED","timeFrame":"Tumor assessments as assessed by investigator were conducted at every 8 weeks from screening until documented disease progression, up to 30 months; based on cutoff date: 19 September 2018.","title":"Duration of Response (DR) Based on BICR Assessment","type":"SECONDARY","unitOfMeasure":"months"}